雷替曲塞经TACE治疗原发性巨块型肝癌的临床疗效评价

Clinical Curative Effect of Raltitrexed therapy of Primary Liver Cancer Through TACE

目的评价雷替曲塞经TACE治疗原发性巨块型肝癌的临床疗效。方法回顾性分析2013年7月至2015年8月本院TACE治疗原发性巨块型肝癌患者56例临床资料,根据术中化疗方案分为两组:5-FU组(A组)24例,雷替曲塞组(B组)32例。比较两组术后临床疗效、不良反应及生存期。结果临床疗效A组有效率(RR)29.2%、疾病控制率(DCR)75.0%,B组37.5%、78.1%,两组比较均无统计学差异(P>0.05);不良反应A组与B组比较无统计学差异(P>0.05);A组平均生存期及中位生存期为9.86个月、8.80个月,B组为12.78个月、13.70个月,B组平均生存期及中位生存期均明显大于A组,差异具有统计学意义(P<0.05)。结论雷替曲塞用于TACE治疗原发性巨块型肝癌的临床疗效及不良反应与5-FU相当,但雷替曲塞能显著延长患者生存期。

Objective To evaluate the clinical curative effect of Raltitrexed treating massive primary liver cancer through TACE. Methods A retrospective analysis was made on 56 patients that had been hospitalized in our hospital and treated by TACE due to massive primary liver cancer from July 2013 to August 2015. These subjects were randomized into two groups according to intra-operative chemotherapy schemes： 24 cases in 5-Fu group（ group A） and 32 cases in Raltitrexed group（ group B）. The clinical curative effect,adverse reactions and survival length of two groups were compared.Results RR of clinical curative effect group A was 29. 2%,DCR 75. 0%; group B RR 37. 5%,DCR 78. 1%; the two groups had no statistical difference（ P〈0. 05）; the two groups had no statistical difference in adverse reactions（ P〈0. 05）; the average survival length and median survival length of group A were 9. 86 months and 8. 80 months,respectively; for group B were 12. 78 months and 13. 70 months. The average survival length and median survival length of group B were significantly longer than that of group A and the differences had statistical difference（ P〈0. 05）. Conclusion The clinical curative effect and adverse reactions of Raltitrexed through TACE treating massive primary liver cancer are equivalent to 5-FU,but Raltitrexed can significantly prolong the survival length of patients. Larger sample size and multi-center study are still in need for further research.